An observational study in Esophageal Cancer (EsC), sponsored by Nanfang Hospital, Southern Medical University. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-04-14.
Sponsored by Nanfang Hospital, Southern Medical University · Observational
This single-center, retrospective, 7-year observational study aims to investigate prognostic factors in esophageal cancer patients. Adults (≥18 years) with histologically confirmed esophageal cancer who received antitumor therapy between January 2017 and December 2024 were consecutively enrolled. Patient-level data (clinical characteristics, routine laboratory tests, tumor information, and treatment details) were retrospectively collected from electronic medical records to analyze key factors influencing treatment efficacy.
1,593 studies on the registry are indexed under Esophageal Neoplasms; 460 are open to participants now.
This study's planned enrollment of 500 is above the median of 200 across 340 observational studies indexed under Esophageal Neoplasms.
Browse Esophageal Neoplasms studies →Nanfang Hospital, Southern Medical University is the lead sponsor of 480 studies on the registry; 212 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Esophageal Cancer Patients
Exclusion Criteria:
Participants will receive definitive radiotherapy or radiotherapy-based combined modality therapy.
Other: radiotherapy
Participants will receive immune checkpoint inhibitors as monotherapy or in combination with other therapies.
Drug: Immunotherapy
Participants will undergo radical esophagectomy with or without neoadjuvant/adjuvant therapy.
Procedure: surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
Definitive radiotherapy or radiotherapy-based combined modality therapy
Immune checkpoint inhibitors as monotherapy or in combination with other therapies
Radical esophagectomy with or without neoadjuvant/adjuvant therapy
Overall Survival (OS)
The length of time from the start of treatment until death from any cause, evaluating the long-term survival benefit of the combined therapy.
Time frame: From the date of treatment initiation to the date of death from any cause,assessed up to 120 months.
Pathologic Complete Response ( pCR )
The absence of residual viable tumor cells in both the primary esophageal tumor and regional lymph nodes after completion of surgery, indicating a complete pathological response.
Time frame: Perioperative
Major Pathological Response Rate (MPR)
The proportion of patients with ≤10% residual viable tumor cells in resected specimens
Time frame: Perioperative
Progression-Free Survival (PFS)
The duration from treatment start until radiologically confirmed disease progression (per RECIST v1.1) or death from any cause, evaluating therapeutic efficacy in delaying tumor growth.
Time frame: From treatment initiation to disease progression or death, assessed up to 100 months
Plan to share: No
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nanfang Hospital, Southern Medical University